Pattern baldness rarely announces itself. It shows up as a widening part or a thinner crown, and the person standing in front of the mirror wants to know one thing: can the clock be slowed? A DHT blocker is the medical answer most dermatologists reach for, and it works by choking off the enzyme that manufactures dihydrotestosterone in the first place.
For the full breakdown, see our best Dht Blockers for Hair Loss guide.
Two drugs do this job. One carries a federal green light, the other does not. Below is what each actually does, what the evidence supports, and where the real limits sit.
How Do DHT Blockers Actually Work?
DHT blockers inhibit 5α-reductase, the enzyme that converts testosterone into dihydrotestosterone, so less DHT reaches hair follicles that are genetically sensitive to it. That sensitivity drives androgenetic alopecia — the medical name for pattern hair loss — by shrinking follicles over time until they stop producing visible strands.
The relevant enzyme comes in two forms, Type I and Type II. Finasteride targets Type II specifically, which is the form most active in the scalp and prostate. Dutasteride hits both. That distinction explains most of the difference between the two drugs, and it is also why “stronger” is not the same as “better.”
Lowering DHT slows follicular miniaturization. It does not reverse scarring, and it does not touch shedding caused by thyroid disease, telogen effluvium, alopecia areata, nutritional deficiency, or medication effects. A clinician should confirm the diagnosis before anyone opens a pill bottle.
Finasteride vs. Dutasteride: Where They Differ
| Feature | Finasteride | Dutasteride |
|---|---|---|
| FDA status for hair loss | Approved, men only | Not approved — off-label |
| Enzyme blocked | Type II 5α-reductase | Type I and Type II |
| Labeled hair-loss dose | 1 mg daily | No US hair-loss label |
| Reported serum DHT drop | About 70% | About 99% |
| Half-life | 6–8 hours | 4–5 weeks |
| Labeled scalp areas | Vertex and anterior mid-scalp | Not established |
| Time to judge benefit | 3 months or longer | Same general expectation |
Finasteride (Propecia) won FDA approval for androgenetic alopecia on December 19, 1997. Dutasteride (Avodart) has approval for hair loss in Japan and South Korea, but no US label for the condition — so any American prescription for this use is off-label, and that is a conversation for a doctor, not a checkout page.
The half-life gap matters more than people expect. Finasteride clears in roughly 6–8 hours; dutasteride lingers 4–5 weeks, which means side effects can persist well after the last dose.
Cost swings widely with generic versus brand status, pharmacy, insurance, and discount programs, so no single figure holds true — ask the pharmacy directly. Many people comparing options before that call start by reading a tested DHT blocker roundup to understand what’s on the shelf.
The FDA label spells out the men-only indication and warns that women who are or may become pregnant should not handle crushed or broken tablets, because finasteride can cause abnormalities in the development of male genitalia.
What DHT Blockers Cannot Do
Stopping treatment reverses the benefit within roughly 12 months, and the drug never eliminates all DHT. Both facts are worth saying plainly: this is a maintenance commitment, not a fix.
Minoxidil is commonly lumped in with DHT blockers and does not belong there.
Supplements and cosmetic shampoos sold as “natural DHT blockers” should not be treated as equivalent to prescription 5α-reductase inhibitors. The clinical evidence behind them is thin, and no standardized effective version exists.
A normal routine looks like this: confirm the pattern with a qualified clinician, review medical history and reproductive plans, take the labeled 1 mg daily dose of finasteride if prescribed, and give it three months or more before judging. Do not swap in dutasteride or combine the two drugs without discussing the off-label status and the long half-life with the prescriber.
More DHT suppression is not automatically safer. The choice rests on diagnosis, approval status, risk profile, and clinician judgment — not on which number looks bigger.
Sources
- U.S. Food and Drug Administration. “Propecia (finasteride) Tablets Prescribing Information, 2022” Supplies the approved indication, 1 mg dose, labeling warnings, and approval context.
- StatPearls / NCBI Bookshelf. “Finasteride” Supports the mechanism, half-life, and DHT-reduction figures.
- StatPearls / NCBI Bookshelf. “Dutasteride” Supports the Type I/II inhibition and the four-to-five-week half-life.